Colonial Trust Advisors Decreases Holdings in Kenvue Inc. $KVUE

Colonial Trust Advisors trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 27.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,079 shares of the company’s stock after selling 46,500 shares during the quarter. Colonial Trust Advisors’ holdings in Kenvue were worth $2,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of KVUE. Norges Bank bought a new position in Kenvue in the second quarter valued at about $537,418,000. Independent Franchise Partners LLP increased its position in shares of Kenvue by 233.4% during the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. American Century Companies Inc. increased its position in shares of Kenvue by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares during the last quarter. Amundi lifted its stake in shares of Kenvue by 82.5% in the 2nd quarter. Amundi now owns 14,509,890 shares of the company’s stock worth $305,446,000 after purchasing an additional 6,559,261 shares during the period. Finally, Mondrian Investment Partners LTD purchased a new position in shares of Kenvue in the third quarter worth approximately $79,269,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.4%

Shares of KVUE stock opened at $19.02 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.96. The stock has a fifty day simple moving average of $17.61 and a two-hundred day simple moving average of $17.55. The firm has a market capitalization of $36.46 billion, a PE ratio of 24.71, a PEG ratio of 4.34 and a beta of 0.59. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the business earned $0.26 earnings per share. The business’s revenue was up 3.2% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Citigroup upped their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. UBS Group raised their target price on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Finally, Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Three analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.50.

Insider Transactions at Kenvue

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of Kenvue stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by company insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.